Revision 5

#88183Store at -20C

Cell Signaling Technology

Orders: 877-616-CELL (2355) [email protected]

Support: 877-678-TECH (8324)

Web: [email protected] cellsignal.com

3 Trask LaneDanversMassachusetts01923USA
For Research Use Only. Not for Use in Diagnostic Procedures.
Applications:

WB, IP, IHC-Bond, IHC-P, FC-FP

REACTIVITY:

H

SENSITIVITY:

Endogenous

MW (kDa):

18-30

Source/Isotype:

Rabbit IgG

UniProt ID:

#Q02223

Entrez-Gene Id:

608

Product Information

Product Usage Information

Application Dilution
Western Blotting 1:8000
Immunoprecipitation 1:800
IHC Leica Bond 1:150 - 1:600
Immunohistochemistry (Paraffin) 1:300 - 1:1200
Flow Cytometry (Fixed/Permeabilized) 1:1600 - 1:6400

Storage

Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

For a carrier-free (BSA and azide free) version of this product see product #84031.

Specificity / Sensitivity

TNFRSF17/BCMA (E6D7B) Rabbit mAb recognizes endogenous levels of total TNFRSF17/BCMA protein. This antibody displays some non-specific staining of peripheral and CNS tissue when used for IHC-P.

Species Reactivity:

Human

Source / Purification

Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Leu115 of human TNFRSF17/BCMA protein.

Background

B cell maturation antigen (BCMA/TNFRSF17/CD269) is a transmembrane glycoprotein and member of the TNFR superfamily (1). BCMA expression is largely restricted to the B cell lineage. Pro-survival signaling through this receptor plays a pivotal role in humoral immunity by regulating B cell maturation and plasma cell differentiation upon binding its ligands, BAFF and APRIL (2-6). BCMA is expressed in a number of B cell malignancies and has garnered much attention as a novel therapeutic target for the treatment of multiple myeloma due to its selective and elevated expression on the cell surface of malignant plasma cells (7-10).

  1. Madry, C. et al. (1998) Int Immunol 10, 1693-702.
  2. Chiu, A. et al. (2007) Blood 109, 729-39.
  3. Avery, D.T. et al. (2003) J Clin Invest 112, 286-97.
  4. O'Connor, B.P. et al. (2004) J Exp Med 199, 91-8.
  5. Darce, J.R. et al. (2007) J Immunol 178, 5612-22.
  6. Xu, S. and Lam, K.P. (2001) Mol Cell Biol 21, 4067-74.
  7. Carpenter, R.O. et al. (2013) Clin Cancer Res 19, 2048-60.
  8. Tai, Y.T. et al. (2006) Cancer Res 66, 6675-82.
  9. Moreaux, J. et al. (2004) Blood 103, 3148-57.
  10. Tai, Y.T. et al. (2014) Blood 123, 3128-38.

Species Reactivity

Species reactivity is determined by testing in at least one approved application (e.g., western blot).

Western Blot Buffer

IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.

Applications Key

WB: Western Blotting IP: Immunoprecipitation IHC-Bond: IHC Leica Bond IHC-P: Immunohistochemistry (Paraffin) FC-FP: Flow Cytometry (Fixed/Permeabilized)

Cross-Reactivity Key

H: human M: mouse R: rat Hm: hamster Mk: monkey Vir: virus Mi: mink C: chicken Dm: D. melanogaster X: Xenopus Z: zebrafish B: bovine Dg: dog Pg: pig Sc: S. cerevisiae Ce: C. elegans Hr: horse GP: Guinea Pig Rab: rabbit All: all species expected

Trademarks and Patents

Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
Alexa Fluor is a registered trademark of Life Technologies Corporation.
All other trademarks are the property of their respective owners. Visit cellsignal.com/trademarks for more information.

Limited Uses

Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.

Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.

Revision 5
#88183

TNFRSF17/BCMA (E6D7B) Rabbit mAb

Western Blotting Image 1: TNFRSF17/BCMA (E6D7B) Rabbit mAb Expand Image
Western blot analysis of extracts from 293T cells, mock transfected (-) or transfected with a construct expressing full-length Myc/DDK-tagged human TNFRSF17 protein (hTNFRSF17-Myc/DDK; +), using TNFRSF17/BCMA (E6D7B) Rabbit mAb (upper), DYKDDDDK Tag Antibody #2368 (middle), and β-Actin (D6A8) Rabbit mAb #8457 (lower).
Western Blotting Image 2: TNFRSF17/BCMA (E6D7B) Rabbit mAb Expand Image
Western blot analysis of extracts from various cell lines using TNFRSF17/BCMA (E6D7B) Rabbit mAb (upper) and β-Actin (D6A8) Rabbit mAb #8457 (lower). As expected, TNFRSF17/BCMA protein expression is not detected in either HeLa or CCRF-CEM cells.
Western Blotting Image 3: TNFRSF17/BCMA (E6D7B) Rabbit mAb Expand Image
Western blot analysis of extracts from U266 cells, untreated (-) or treated with PNGase F (+), using TNFRSF17/BCMA (E6D7B) Rabbit mAb (upper) and β-Actin (D6A8) Rabbit mAb #8457 (lower).
Immunoprecipitation Image 1: TNFRSF17/BCMA (E6D7B) Rabbit mAb Expand Image
Immunoprecipitation of TNFRSF17/BCMA from U266 cell extracts. Lane 1 is 10% input, lane 2 is Rabbit (DA1E) mAb IgG XP® Isotype Control #3900, and lane 3 is TNFRSF17/BCMA (E6D7B) Rabbit mAb. Western blot analysis was performed using TNFRSF17/BCMA (E6D7B) Rabbit mAb. A HRP-conjugated heavy chain specific secondary antibody was used for detection.
Immunohistochemistry Image 1: TNFRSF17/BCMA (E6D7B) Rabbit mAb Expand Image
Immunohistochemical analysis of paraffin-embedded human colon adenocarcinoma using TNFRSF17/BCMA (E6D7B) Rabbit mAb performed on the Leica® BOND Rx.
Immunohistochemistry Image 2: TNFRSF17/BCMA (E6D7B) Rabbit mAb Expand Image
Immunohistochemical analysis of paraffin-embedded human esophageal carcinoma using TNFRSF17/BCMA (E6D7B) Rabbit mAb performed on the Leica® BOND Rx.
Immunohistochemistry Image 1: TNFRSF17/BCMA (E6D7B) Rabbit mAb Expand Image
Immunohistochemical analysis of paraffin-embedded human mutiple myeloma using TNFRSF17/BCMA (E6D7B) Rabbit mAb.
Immunohistochemistry Image 2: TNFRSF17/BCMA (E6D7B) Rabbit mAb Expand Image
Immunohistochemical analysis of paraffin-embedded human papillary carcinoma of the breast using TNFRSF17/BCMA (E6D7B) Rabbit mAb.
Immunohistochemistry Image 3: TNFRSF17/BCMA (E6D7B) Rabbit mAb Expand Image
Immunohistochemical analysis of paraffin-embedded human colon carcinoma using TNFRSF17/BCMA (E6D7B) Rabbit mAb.
Immunohistochemistry Image 4: TNFRSF17/BCMA (E6D7B) Rabbit mAb Expand Image
Immunohistochemical analysis of paraffin-embedded human bone marrow using TNFRSF17/BCMA (E6D7B) Rabbit mAb.
Immunohistochemistry Image 5: TNFRSF17/BCMA (E6D7B) Rabbit mAb Expand Image
Immunohistochemical analysis of paraffin-embedded human normal colon using TNFRSF17/BCMA (E6D7B) Rabbit mAb.
Immunohistochemistry Image 6: TNFRSF17/BCMA (E6D7B) Rabbit mAb Expand Image
Immunohistochemical analysis of paraffin-embedded human lymph node using TNFRSF17/BCMA (E6D7B) Rabbit mAb.
Immunohistochemistry Image 7: TNFRSF17/BCMA (E6D7B) Rabbit mAb Expand Image
Immunohistochemical analysis of paraffin-embedded U266 cell pellet (left, positive) or HeLa cell pellet (right, negative) using TNFRSF17/BCMA (E6D7B) Rabbit mAb.
Flow Cytometry Image 1: TNFRSF17/BCMA (E6D7B) Rabbit mAb Expand Image
Flow cytometric analysis of Jurkat cells (blue, negative) and NCI-H929 cells (green, positive) using TNFRSF17/BCMA (E6D7B) Rabbit mAb (solid lines) or a concentration-matched Rabbit (DA1E) mAb IgG XP® Isotype Control #3900 (dashed lines). Anti-rabbit IgG (H+L), F(ab')2 Fragment (Alexa Fluor® 488 Conjugate) #4412 was used as a secondary antibody.